Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

FKBP12 PROTAC dTAG-13

Catalog No. T11291Cas No. 2064175-41-1
Alias dTAG-13

FKBP12 PROTAC dTAG-13 (dTAG-13) is a heterobifunctional degrader that targets FKBP12F36V with FKBP12F36V expressed in-frame with a protein of interest, and selectively degrades the BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to the E3 ubiquitin ligase CRBN.

FKBP12 PROTAC dTAG-13

FKBP12 PROTAC dTAG-13

Catalog No. T11291Alias dTAG-13Cas No. 2064175-41-1
FKBP12 PROTAC dTAG-13 (dTAG-13) is a heterobifunctional degrader that targets FKBP12F36V with FKBP12F36V expressed in-frame with a protein of interest, and selectively degrades the BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to the E3 ubiquitin ligase CRBN.
Pack SizePriceAvailabilityQuantity
5 mg$1,35035 days
Bulk & Custom
Add to Cart
Questions
View More
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
FKBP12 PROTAC dTAG-13 (dTAG-13) is a heterobifunctional degrader that targets FKBP12F36V with FKBP12F36V expressed in-frame with a protein of interest, and selectively degrades the BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to the E3 ubiquitin ligase CRBN.
In vitro
dTAG-13 treatment leads to rapid and potent degradation of the BRD4 fusion chimera in the heterozygous and homozygous knock-in clones, with no effect on endogenous FKBP12WT.TAG-13 (1-1000 nM; 4 hours; 293FTWT cells) treatment potently reduces FKBP12F36V-Nluc levels in 293FTWT cell, indicating the requirement of CRBN for the observed effects. Treatment of MV4;11 cells expressing BRD4(short)-FKBP12F36V with dTAG-13 leads to robust degradation of BRD4. dTAG-13 treatment leads to rapid degradation of BRD4 within one hou.
In vivo
After bone marrow transplantation of mice with MV4;11 cells expressing luc-FKBP12F36V, monitoring of the bioluminescent signal reveals a significant, rapid, and lasting reduction in bioluminescence four hours after dTAG-13 administration, compared to the vehicle control, signifying effective breakdown of luc-FKBP12F36V. Moreover, 28 hours post the final dTAG-13 treatment, bioluminescence levels equalize between the dTAG-13 and vehicle groups, indicating recovery.
AliasdTAG-13
Chemical Properties
Molecular Weight1049.17
FormulaC57H68N4O15
Cas No.2064175-41-1
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy FKBP12 PROTAC dTAG-13 | purchase FKBP12 PROTAC dTAG-13 | FKBP12 PROTAC dTAG-13 cost | order FKBP12 PROTAC dTAG-13 | FKBP12 PROTAC dTAG-13 chemical structure | FKBP12 PROTAC dTAG-13 in vivo | FKBP12 PROTAC dTAG-13 in vitro | FKBP12 PROTAC dTAG-13 formula | FKBP12 PROTAC dTAG-13 molecular weight